lysophosphatidic acid has been researched along with aspirin in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (42.86) | 29.6817 |
| 2010's | 4 (57.14) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bao, HQ; Huang, SC; Li, ZG; Meng, XL; Ren, B; Sun, YH; Tang, CS; Wu, QZ; Yao, CS | 1 |
| Fishman, DA; Kang, S; Luo, R; Meng, Y; Smicun, Y | 1 |
| Cong, HM; Ju, WP; Li, ZG; Man, HH; Wang, DZ; Wu, QZ; Wu, XJ; Yu, ZC; Zhan, X | 1 |
| Kinoshita, M; Morito, K; Ohmoto, M; Satouchi, K; Tanaka, T; Tokumura, A; Urikura, M | 1 |
| Gao, LS; Jiang, B; Liu, F; Sun, ZR; Wang, HB; Wu, QZ; Yan, SG; Yao, CS | 1 |
| Abdolahi, A; Block, RC; Brenna, JT; Georas, SN; Lawrence, P; Mousa, SA; Phipps, RP; Tu, X | 1 |
| Contursi, A; Dovizio, M; Grande, R; Patrignani, P; Sacco, A | 1 |
1 review(s) available for lysophosphatidic acid and aspirin
| Article | Year |
|---|---|
Platelets as crucial partners for tumor metastasis: from mechanistic aspects to pharmacological targeting.
Topics: Animals; Aspirin; Blood Platelets; Eicosanoids; Epithelial-Mesenchymal Transition; Humans; Lysophospholipids; Molecular Targeted Therapy; Neoplasm Metastasis; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Platelet Membrane Glycoproteins; Purinergic P2Y Receptor Antagonists; Receptors, Prostaglandin E, EP3 Subtype | 2017 |
1 trial(s) available for lysophosphatidic acid and aspirin
| Article | Year |
|---|---|
The effects of aspirin on platelet function and lysophosphatidic acids depend on plasma concentrations of EPA and DHA.
Topics: Adult; Aged; Aspirin; Blood Platelets; Diabetes Mellitus, Type 2; Docosahexaenoic Acids; Eicosapentaenoic Acid; Fatty Acids, Unsaturated; Female; Humans; Lysophospholipids; Male; Middle Aged; Platelet Aggregation Inhibitors | 2015 |
5 other study(ies) available for lysophosphatidic acid and aspirin
| Article | Year |
|---|---|
[Effects of aspirin on lowering plasma level of lysophosphatidic acid in cerebral ischemic patients].
Topics: Aged; Aspirin; Brain Ischemia; Female; Fibrinolytic Agents; Humans; Infant; Lysophospholipids; Male; Middle Aged | 2004 |
Selective induction of cyclooxygenase-2 plays a role in lysophosphatidic acid regulated Fas ligand cell surface presentation.
Topics: Animals; Antigen Presentation; Antigens, Surface; Apoptosis; Aspirin; Cell Line, Tumor; Cell Membrane; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Enzyme Activation; Enzyme Induction; Enzyme Inhibitors; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Fas Ligand Protein; Female; Flavonoids; Humans; Lymphocyte Activation; Lymphocytes; Lysophospholipids; Membrane Glycoproteins; Nitrobenzenes; Ovarian Neoplasms; Quinazolines; Signal Transduction; Sulfonamides; Tumor Necrosis Factors; Tyrphostins | 2006 |
Influence of acetylsalicylate on plasma lysophosphatidic acid level in patients with ischemic cerebral vascular diseases.
Topics: Aspirin; Biomarkers; Blood Platelets; Brain Ischemia; Down-Regulation; Female; Humans; Lysophospholipids; Male; Middle Aged; Phosphorus; Platelet Aggregation Inhibitors; Treatment Outcome | 2008 |
Orally administered phosphatidic acids and lysophosphatidic acids ameliorate aspirin-induced stomach mucosal injury in mice.
Topics: Administration, Oral; Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Drug Evaluation, Preclinical; In Vitro Techniques; Lysophospholipids; Male; Mice; Mice, Inbred ICR; Phosphatidic Acids; Phospholipases A2; Receptors, Lysophosphatidic Acid; Stomach; Stomach Ulcer | 2013 |
Patients with risk factors have higher plasma levels of lysophosphatidic acid: a promising surrogate marker for blood platelet activation.
Topics: Aspirin; Biomarkers; Blood Platelets; Cross-Sectional Studies; Female; Humans; Hyperlipidemias; Hypertension; Lysophospholipids; Male; Middle Aged; Pilot Projects; Platelet Activation; Risk Factors | 2014 |